Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th American Society of Hematology ...

"The data being presented this year at ASH demonstrate Syndax's commitment to develop revumenib as a practice-changing therapy for adult and pediatric patients with acute leukemias," said Neil ...

Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX) is a biotechnology company focused on developing innovative cancer therapies. With recent FDA approvals and upcoming regulatory decisions, Syndax is ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host ...